• Explore /
  • Poster
  • / DNA vaccine with pembrolizumab to elicit antitumor responses in patients with metastatic, castration-resistant prostate cancer (mCRPC).

DNA vaccine with pembrolizumab to elicit antitumor responses in patients with metastatic, castration-resistant prostate cancer (mCRPC).

Abstract Poster

Authors

null

Douglas G. McNeel

University of Wisconsin, Madison, WI

Douglas G. McNeel, Jens C. Eickhoff, Robert Jeraj, Mary Jane Staab, Jane Straus, Brian Rekoske, Glenn Liu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO-SITC Clinical Immuno-Oncology Symposium

Session Type

Poster Session

Session Title

Poster Session A

Track

Biomarkers and Inflammatory Signatures,Humoral Immunity for Diagnosis and Therapy,Immune Checkpoints and Stimulatory Receptors,Modulating Innate Immunity,Therapies Targeting T cells

Sub Track

Vaccines: Treatment and Prevention

Clinical Trial Registration Number

NCT02499835

Citation

J Clin Oncol 35, 2017 (suppl 7S; abstract 168)

DOI

10.1200/JCO.2017.35.7_suppl.168

Abstract #

168

Poster Bd #

J7

Abstract Disclosures

Similar Posters

First Author: David D. Chism

First Author: Gero Kramer

First Author: Rahul Raj Aggarwal

First Author: Evan Y. Yu